Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma

Endocrine Pathology

Volumn 23, Issue 1, 2012, Pages 34-42

  Favier, Judith ^a,b   Igaz, Peter ^c   Burnichon, Nelly ^a,b,d   Amar, Laurence ^a,d   Libé, Rossella ^e,f,g   Badoual, Cécile ^a,b,d   Tissier, Frédérique ^b,e,f   Bertherat, Jérôme ^e,f,g   Plouin, Pierre François ^a,d,g   Jeunemaitre, Xavier ^a,b,d   Gimenez Roqueplo, Anne Paule ^a,b,d,g  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSTITUT COCHIN   (France)

^f Institut Cochin ^*  (France)

^g INSTITUT NATIONAL DU CANCER   (France)

Author keywords

Angiogenesis; Hypoxia; Paraganglioma; Pheochromocytoma; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 2; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR A; ENDOTHELIN RECEPTOR B; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN NF1; PROTEIN RET; PROTEIN TMEM127; S6 KINASE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE X; TRANSCRIPTOME; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ANTIANGIOGENIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CLASSIFICATION; TUMOR VASCULARIZATION;

ADRENAL GLAND NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84858705282     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-011-9189-0     Document Type: Article

References (40)

1. Gimenez-Roqueplo AP, Burnichon N, Amar L, Favier J, Jeunemaitre X, Plouin PF Recent advances in the genetics of phaeochromocytoma and functional paraganglioma. Clinical and experimental pharmacology & physiology 35: 376-379, 2008. (Pubitemid 351326766)
2. Mulligan LM, Kwok JB, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460, 1993. (Pubitemid 23179393)
3. Wallace MR, Marchuk DA, Andersen LB et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249: 181-186, 1990.
4. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320., 1993. (Pubitemid 23231974)
5. Burnichon N, Briere JJ, Libe R et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19: 3011-3020, 2010.
6. Astuti D, Latif F, Dallol A et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69: 49-54., 2001. (Pubitemid 32614017)
7. Niemann S, Muller U Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26: 268-270, 2000.
8. Baysal BE, Ferrell RE, Willett-Brozick JE et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848-851., 2000. (Pubitemid 30084326)
9. Bayley JP, Kunst HP, Cascon A et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 11: 366-372, 2010.
10. QinY,Yao L, King EE et al. Germlinemutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 42: 229-233, 2010.
11. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43: 663-667, 2011.
12. Lloyd R, Tischler A, Kimura N, McNicol A, Young JW. Adrenal tumours: Introduction. In: DeLellis RA LR, Heitz PU, Eng C, eds. WHO classification of tumours - Pathology and Genetics - Tumours of endocrine organs. IARC Press, Lyon, 2004.
13. Amar L, Baudin E, Burnichon N et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92: 3822-3828, 2007. (Pubitemid 47607629)
14. Gimenez-Roqueplo AP, Favier J, Rustin P et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63: 5615-5621, 2003. (Pubitemid 37139886)
15. Pasini B, Stratakis CA SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytomaparaganglioma syndromes. Journal of internal medicine 266: 19-42, 2009.
16. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14: 569-585, 2007. (Pubitemid 350074048)
17. Ohji H, Sasagawa I, Iciyanagi O, Suzuki Y, Nakada T Tumour angiogenesis and Ki-67 expression in phaeochromocytoma. BJU Int 87: 381-385., 2001. (Pubitemid 32240854)
18. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. Apmis 111: 458-464, 2003. (Pubitemid 36735003)
19. Liu Q, Djuricin G, Staren ED et al. Tumor angiogenesis in pheochromocytomas and paragangliomas. Surgery 120: 938- 942; discussion 942-933., 1996.
20. Rooijens PP, de Krijger RR, Bonjer HJ et al. The significance of angiogenesis in malignant pheochromocytomas. Endocr Pathol 15: 39-45, 2004. (Pubitemid 38951807)
21. Zielke A, Middeke M, Hoffmann S et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132: 1056-1063; discussion 1063, 2002.
22. Feng F, Zhu Y, Wang X et al. Predictive factors for malignant pheochromocytoma: analysis of 136 patients. The Journal of urology 185: 1583-1590, 2011.
23. Favier J, Plouin PF, Corvol P, Gasc JM Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161: 1235-1246, 2002.
24. Kolomecki K, Stepien H, Bartos M, Kuzdak K Usefulness of VEGF, MMP-2,MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocrine regulations 35: 9-16, 2001. (Pubitemid 33711948)
25. Takekoshi K, Isobe K, Yashiro T et al. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci 74: 863-871, 2004. (Pubitemid 37501135)
26. Favier J, Gimenez-Roqueplo AP Pheochromocytomas: The (Pseudo)-hypoxic hypothesis. Best Pract Res Clin Endocrinol Metab 24: 957-968, 2010.
27. Dahia PL, Ross KN, Wright ME et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1: 72-80, 2005.
28. Lopez-Jimenez E,Gomez-LopezG, Leandro-Garcia LJ et al. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 24: 2382-2391, 2010.
29. Burnichon N, Vescovo L, Amar L et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 20: 3974-3985, 2011.
30. Plouin PF, Gimenez-Roqueplo AP Initial work-up and longterm follow-up in patients with phaeochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 20: 421-434, 2006.
31. Favier J, Kempf H, Corvol P, Gasc J Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase. FEBS Lett 462: 19-24, 1999.
32. Favier J, Briere JJ, Burnichon N et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PloS one 4: e7094, 2009.
33. Jimenez C, Cabanillas ME, Santarpia L et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94: 386-391, 2009.
34. Joshua AM, Ezzat S, Asa SL et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 94: 5-9, 2009.
35. Park KS, Lee JL, Ahn H et al. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 39: 327-331, 2009.
36. Tuthill M, Barod R, Pyle L et al. A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ Case Rep 2009, 2009.
37. Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 27: 460- 463, 2009.
38. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 41: 697-702, 2009.
39. Ebos JM, Kerbel RS Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8: 210-221, 2011.
40. Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338, 2009.